Menopause and estrogen deficiency as a risk factor in dementing illness: Hypothesis on the biological basis

Maturitas

Volumn 31, Issue 2, 1999, Pages 95-101

  Solerte, Sebastiano B ^a   Fioravanti, Marisa ^a   Racchi, Marco ^b   Trabucchi, Marco ^c   Zanetti, Orazio ^b   Govoni, Stefano ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Alzheimer's disease; Amyloid precursor protein; Apolipoprotein E; Estrogens; Glucose metabolism; Neuroimmune interactions; Neuroprotection; Risk factors

Indexed keywords

AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; ESTROGEN;

ALZHEIMER DISEASE; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; GLUCOSE METABOLISM; HUMAN; HYPOTHESIS; MENOPAUSE; NEUROIMMUNOLOGY; NEUROPROTECTION; REVIEW; RISK FACTOR;

EID: 0032972490     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(98)00111-X     Document Type: Article

References (68)

1. Sherwin B.B. Hormones, mood and cognitive functioning in postmenopausal women. Obstet Gynecol. 87:1996;20-26.
2. Sherwin B.B. Estrogen, the brain, and memory. Menopause. 3:1996;97-105.
3. Costa A., Nappi R.E., Sinforiani E., Bono G., Poma A., Nappi G. Cognitive function at menopause: neuroendocrine implications for the study of the aging brain. Funct Neurol. 12:1997;175-180.
4. Paganini-Hill A., Henderson V.W. Estrogen deficiency increases risk of Alzheimer's disease in women. Am J Epidemiol. 140:1994;256-261.
5. Fillit H., Weinreb H., Cholst I. et al. Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type. Psychoneuroendocrinology. 11:1996;337-345.
6. Honjo H., Ogino Y., Naitoh K. et al. In vivo effects by estrone sulfate on the nervous system - senile dementia (Alzheimer's type). J Steroid Biochem. 34:1989;521-525.
7. Ohkura T., Isse K., Akazawa K., Hamamoto M., Yaoi Y., Hagino N. Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type. Endocrine J. 41:1994;361-371.
8. Phillips S.M., Sherwin B.B. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology. 17:1992;485-495.
9. Sherwin B.B. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology. 13:1988;345-357.
10. Simpkins J.W., Singh M., Bishop J. The potential role for estrogen replacement therapy in the treatment of the cognitive decline and neurodegeneration associated with Alzheimer's disease. Neurobiol Aging. 15(Suppl 2):1994;S195-S197.
11. Schneider L.S., Farlow M.R., Henderson V.W., Pogoda J.M. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology. 46:1996;1580-1584.
12. Fillit H. Future therapeutic developments of estrogen use. J Clin Pharmacol. 35(Suppl 9):1995;25S-28.
13. Funk J.L., Mortel K.F., Meyer J.S. Effects of estrogen replacement therapy on cerebral perfusion and cognition amongst postmenopausal women. Dementia. 2:1991;268-272.
14. De La Torre J.C. Cerebromicrovascular pathology in Alzheimer's disease compared to normal aging. Gerontology. 43:1997;26-43.
15. Kampen D.L., Sherwin B.B. Estrogen use and verbal memory in healthy postmenopausal women. Obstet Gynecol. 83:1994;979-983.
16. Birge S.J. Is there a role for estrogen replacement therapy in the prevention and treatment of dementia? J Am Geriatr Soc. 44:1996;865-870.
17. Ohkura T., Isse K., Akazawa K., Hamamoto M., Yaoi Y., Hagino N. Long-term estrogen replacement therapy in female patients with dementia of the Alzheimer type: 7 case reports. Dementia. 6(2):1995;99-107.
18. Barret Connor E., Kritz Silverstein D. Estrogen replacement therapy and cognitive function in older women. J Am Med Assoc. 269(20):1993;2637-2641.
19. Toran-Allerand C.D., Miranda R.C., Bentham W.D.L. et al. Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc Natl Acad Sci USA. 89:1992;4668-4672.
20. Singh M., Meyer E.M., Millard W.J., Simpkins J.W. Ovarian steroid deprivation results in a reversible learning impairment and compromised cholinergic function in female Sprague-Dawley rats. Brain Res. 644:1994;305-312.
21. Toran-Allerand C.D., Ellis L., Pfenninger K.H. Estrogen and insulin synergism in neurite growth enhancement in vitro: mediation of steroid effects by interactions with growth factors. Brain Res. 469:1988;87-100.
22. Sohrabji F., Miranda R.C., Toran-Allerand C.D. Estrogen differentially regulates estrogen and nerve growth factor receptor mRNAs in adult sensory neurons. J Neurosci. 14:1994;459-471.
23. Dluzen D.E., McDermott J.L., Liu B. Estrogen alters MPTP-induced neurotoxicity in female mice: effects on striatal dopamine concentrations and release. J Neurochem. 66:1996;658-666.
24. Behl C., Widmann M., Trapp T., Holsboer F. 17-β-Estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochem Biophys Res Commun. 13:1995;473-482.
25. Crowley W.R. Effects of ovarian hormones on norephinephrine and dopamine turnover in individual hypothalamic and extrahypothalamic nuclei. Neuroendocrinology. 34:1982;381-386.
26. Studd J., Panay N. Hormone replacement therapy in the prevention and treatment of climateric depression. Paoletti R. et al. Women's Health and Menopause. 1997;177-184 Kluwer, Dordrecht.
27. Jaffe A.B., Toran-Allerand C.D., Greengard P., Gandy S.E. Estrogen regulates metabolism of Alzheimer amyloid β precursor protein. J Biol Chem. 269:1994;13065-13068.
28. Ianna P., Racchi M., Cattaneo E. et al. Estrogen effect on brain biology and cognition. Paoletti R. et al. Women's Health and Menopause. 1997;191-198 Kluwer, Dordrecht.
29. Saunders A.M., Hulette C., Welsh-Bohmer K.A. et al. Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease. Lancet. 348:1996;90-93.
30. Frisoni G.B., Govoni S., Geroldi C. et al. Gene dose of the epsilon 4 allele of apolipoprotein E and disease progression in sporadic late onset Alzheimer's disease. Ann Neurol. 37:1995;596-604.
31. Bourassa P.K., Milos P.M., Gaynor B.J., Breslow J.L., Aiello R.J. Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA. 93:1996;10022-10027.
32. Ross R.K., Paganini-Hill A., Mack T.M., Henderson B.E. Cardiovascular benefits of estrogen replacement therapy. Am J Obstet Gynecol. 160:1989;1301-1306.
33. Srivastava R.A.K., Bhasin N., Srivastava N. Apolipoprotein E gene expression in various tissues of mouse and regulation by estrogen. Biochem Mol Biol Int. 38:1996;91-101.
34. Tang M., Jacobs D., Stern Y. et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet. 348:1996;429-432.
35. Mahley R.W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 240:1988;622-630.
36. Bellosta S., Nathan B.P., Orth M. et al. Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells. J Biol Chem. 270:1995;27061-27063.
37. Miller A.E., Neighbour P.A., Katzman R., Aronson M., Lipkowitz R. Immunological studies in senile dementia of the Alzheimer type: evidence for enhanced suppressor cell activity. Ann Neurol. 10:1981;506-511.
38. Rogers J., Luber-Narod J., Styren S.D., Civin W.H. Expression of immune system-associated antigens by cells of human central nervous system: relationship to the pathology of Alzheimer's disease. Neurobiol Aging. 9:1981;339-349.
39. Huberman M., Shalit F., Roth-Deri I. et al. Correlation of cytokine secretion by mononuclear cells of Alzheimer patients and their disease stage. J Neuroimmunol. 52:1994;147-152.
40. McGeer P.L., Rogers J., McGeer E.G. Neuroimmune mechanisms in Alzheimer disease pathogenesis. Alzheimer Dis Assoc Disord. 8:1994;149-158.
41. Singh V.K. Neuroautoimmunity: pathogenetic implications for Alzheimer's disease. Gerontology. 43:1997;79-94.
42. McRae A., Dahlstrim A., Ling E.A. Microglial in neurodegenerative disorders: emphasis on Alzheimer's disease. Gerontology. 43:1997;95-108.
43. Solerte S.B., Fioravanti M., Severgnini S. et al. Enhanced cytotoxic response of natural killer cells to interleukin-2 in Alzheimer's disease. Dementia. 7:1996;343-348.
44. Solerte S.B., Fioravanti M., Severgnini S. et al. DHEA-sulfate and natural killer (NK) cell function in the clinical characterization of Alzheimer's disease. J Endocrinol Invest. 19(Suppl 5):1996;52.
45. Solerte S.B., Fioravanti M., Severgnini S. et al. Excitatory pattern of gamma-interferon on natural killer cell activity in senile dementia of the Alzheimer type. Dement Geriatr Cogn Disord. 8:1997;308-311.
46. Solerte S.B., Fioravanti M., Severgnini S., Cerutti N., Locatelli M., Ferrari E. Variability of natural killer (NK) cell immune function in normal aging and senile dementia: pathophysiological implications. Aging Clin Exp Res. 9(Suppl 4):1997;32-33.
47. Solerte S.B., Fioravanti M., Pascale A., Ferrari E., Govoni S., Battaini F. Increased natural killer cell cytotoxicity in Alzheimer's disease may involve protein kinase C dysregulation. Neurobiol Aging. 19:1998;191-199.
48. Solerte S.B., Cerutti N., Severgnini S., Ferrari E., Fioravanti M. Decreased immunosuppressive effect of cortisol on natural killer cytotoxic activity in senile dementia of the Alzheimer's type. Dement. Geriatr. Cogn. Disord. 9:1998;149-156.
49. Provinciali M., Di Stefano G., Muzzioli M., Garzetti G.G., Ciavattini A. Relationship between 17-β-estradiol and prolactin in the regulation of natural killer cell activity during progression of endometriosis. J Endocrinol Invest. 18:1995;645-652.
50. Grossman C.J. Interactions between the gonadal steroids and the immune system. Science. 227:1985;257-261.
51. Ferguson M.M., Mc Donald F.G. Oestrogen as an inhibitor of human NK cell cytolysis. FEBS Lett. 191:1985;145-148.
52. Hanna N., Schneider M. Enhancement of tumor metastasis and suppression of NK cell activity by β-oestradiol treatment. J Immunol. 130:1983;974-980.
53. Stephenson J. More evidence links NSAID, estrogen use with reduced Alzheimer risk. J Am Med Assoc. 275:1996;1389-1390.
54. Meier-Ruge W., Bertoni-Freddari C., Iwangoff P. Changes in brain glucose metabolism as a key to the pathogenesis of Alzheimer's disease. Gerontology. 40:1994;246-252.
55. Craft S., Zallen G., Baker L.D. Glucose and memory in mild senile dementia of the Alzheimer type. J Clin Exp Neuropsychol. 14:1992;253-267.
56. Manning C.A., Ragozzino M.E., Gold P.E. Glucose enhancement of memory in patients with probable senile dementia of the Alzheimer's type. Neurobiol Aging. 14(6):1993;523-528.
57. Marfaing P., Penicaud L., Broer Y., Mraovitch S., Calando Y., Picon L. Effects of hyperinsulinemia on local cerebral insulin binding and glucose utilization in normoglycemic awake rats. Neurosci Lett. 115:1990;279-285.
58. Palovcik R.A., Phillips M.I., Kappy M.S., Raizada M.K. Insulin inhibits pyramidal neurons in hippocampal slices. Brain Res. 309:1984;187-191.
59. Unger J., McNeill T.H., Moxley R.T., White M., Moss A., Livingston J.N. Distribution of insulin receptor-like immunoreactivity in the rat forebrain. Neuroscience. 31:1989;143-157.
60. Takadera T., Sakura N., Mohri T., Hashimoto T. Toxic effect of a β-amyloid peptide (β22-35) on the hippocampal neuron and its prevention. Neurosci Lett. 161:1993;41-44.
61. Craft S., Newcomer J., Kanne S. et al. Memory improvement following induced hyperinsulinemia in Alzheimer's disease. Neurobiol Aging. 17:1996;123-130.
62. Razay G., Wilcock G.K. Hyperinsulinemia and Alzheimer's disease. Age Ageing. 23:1994;396-399.
63. Solerte S.B., Cerutti N., Fioravanti M. et al. Alterations of 24-h serum insulin profile in patients with senile dementia of Alzheimer's type: potential link with the cognitive derangement. Aging Clin Exp Res. 9(Suppl 4):1997;85.
64. Andersson B., Mattsson L.-A., Hahn L. et al. Estrogen replacement therapy decreases hyperandrogenity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 82:1997;638-643.
65. Zanetti O., Bianchetti A., Govoni S., Trabucchi M. Estrogen replacement therapy and cognitive function in elderly women. Paoletti R. et al. Women's Health and Menopause. 1997;163-168 Kluwer, Dordrecht.
66. Kuller L.H. Hormone replacement therapy and its potential relationship to dementia. J Am Geriatr Soc. 44:1996;878-880.
67. Fratiglioni L., Viitanen M., Vonstrauss E., Tontodonati V., Herlitz A., Winblad B. Very old women at highest risk of dementia and Alzheimer's disease - incidence data from the Kungsholmenproject, Stockholm. Neurology. 48:1997;132-138.
68. Rocca W.A., Hofman A., Brayne C. et al. Frequency and distribution of Alzheimer's disease in Europe: a collaborative study of 1880-1990 prevalence findings. Ann Neurol. 30:1991;381-390.